Anticopper therapy against cancer and diseases of inflammation and fibrosis

Drug Discovery Today

Volumn 10, Issue 16, 2005, Pages 1103-1109

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBON TETRACHLORIDE; CHELATING AGENT; CONCANAVALIN A; COPPER; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BRAIN TUMOR; BREAST CANCER; CANCER; CLINICAL TRIAL; COPPER BLOOD LEVEL; COPPER DEFICIENCY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; FIBROSIS; HEART DISEASE; HEPATITIS; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG FIBROSIS; MESOTHELIOMA; NONHUMAN; PROSTATE CANCER; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; WILSON DISEASE;

ANIMALS; COPPER; FIBROSIS; HUMANS; INFLAMMATION; MOLYBDENUM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PENICILLAMINE; TRIETHYLENETETRAMINE;

EID: 24944451854     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03541-5     Document Type: Review

References (55)

1. Brewer G.J. Wilson's Disease Kasper D.L. Harrison's Principles of Internal Medicine 2004 McGraw-Hill Companies, Inc 2313 2315
2. Brewer G.J. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management 2001 Kluwer Academic Publishers
3. Brewer G.J. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 60 2003 379 385
4. Brewer G.J. Treatment of Wilson's disease with zinc: XV long-term follow-up studies J. Lab. Clin. Med. 132 1998 264 278
5. Walshe J.M. Penicillamine, a new oral therapy for Wilson's disease Am. J. Med. 21 1956 487 495
6. Walshe J.M. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride Lancet 1 1982 643 647
7. Folkman J. Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
8. Brem S.S. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol. 137 1990 1121 1142
9. Brewer G.J. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease Exp. Biol. Med. (Maywood) 226 2001 665 673
10. Brewer G.J., Merajver S.D. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper-a review Integr. Cancer Ther. 1 2002 327 337
11. Goodman V.L. Copper deficiency as an anti-cancer strategy Endocr. Relat. Cancer 11 2004 255 263
12. Pan Q. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis Cancer Res. 62 2002 4854 4859
13. van Golen K.L. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma Neoplasia 4 2002 373 379
14. Cox C.D. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma Laryngoscope 111 2001 696 701
15. Pan Q. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma Mol. Cancer Ther. 2 2003 617 622
16. Cox C. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model Arch. Otolaryngol. Head Neck Surg. 129 2003 781 785
17. Khan M.K. Radiotherapy and antiangiogenic TM in lung cancer Neoplasia 4 2002 164 170
18. Kent M.S. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: A pilot study in a canine animal mode J. Trace Elem. Exp. Med. 17 2004 9 20
19. Brewer G.J. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study Clin. Cancer Res. 6 2000 1 10
20. Brewer G.J. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice J. Lab. Clin. Med. 141 2003 210 216
21. Brewer G.J. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis J. Inorg. Biochem. 98 2004 2160 2167
22. Askari F.K. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice Exp. Biol. Med. (Maywood) 229 2004 857 863
23. Ma S. Tetrathiomolybdate protects against liver injury from acetaminophen in mice The Journal of Applied Research in Clinical and Experimental Therapeutics 4 2004 419 426
24. Linder M.C. Copper regulation of ceruloplasmin in copper-deficient rats Enzyme 24 1979 23 35
25. Yang J.C. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 349 2003 427 434
26. Hurwitz H. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
27. Susman E. Consensus panel: antiangiogenesis drugs unlikely as single agents Oncology Times June 2001
28. Brem S. Phase II trial of copper depletion as angiosuppressive treatment in newly diagnosed Glioblastoma Multiforme: Final report J. Clin. Oncol. (Meeting Abstracts) 22 2004 1530
29. Redman B.G. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer Clin. Cancer Res. 9 2003 1666 1672
30. Pan Q. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade Mol. Cancer Res. 1 2003 701 706
31. Vine A.K., Brewer G.J. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration Trans. Am. Ophthalmol. Soc. 100 2002 73 76
32. Elner S.G. Effects of tetrathiomolybdate in a mouse model of retinal neovascularization Invest. Ophthalmol. Vis. Sci. 46 2005 299 303
33. Brewer G.J. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation J. Cell. Mol. Med. 7 2003 11 20
34. Brewer G.J. Copper lowering therapy with tetrathiomolybdate produces antiangiogenic, anticancer, antifibrotic and antiinflammatory effects Seminars in Integrative Medicine 1 2003 181 190
35. Phan S.H., Kunkel S.L. Lung cytokine production in bleomycin-induced pulmonary fibrosis Exp. Lung Res. 18 1992 29 43
36. Bergman I., Loxly R. Two improved and simplified methods for spectohotometric determination of hydroxyproline Anal. Chem. 35 1963 1961 1965
37. Aleksunes L.M. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride Toxicol. Sci. 83 2005 44 52
38. Kimura K. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A Int. Immunol. 11 1999 1491 1500
39. Lebecque S. A new job for dendritic cells Nat. Immunol. 2 2001 830 831
40. Suarez-Almazor M.E. Penicillamine for rheumatoid arthritis Cochrane Database of Systematic Reviews 2 2000 CD001460
41. Furst D.E., Clements P.J. D-penicillamine is not an effective treatment in systemic sclerosis Scand. J. Rheumatol. 30 2001 189 191
42. Cooper G.J. Regeneration of the heart in diabetes by selective copper chelation Diabetes 53 2004 2501 2508
43. Cameron N.E., Cotter M.A. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J. Clin. Invest. 96 1995 1159 1163
44. Eaton J.W., Qian M. Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy Mol. Cell. Biochem. 2002 234 235 135-142
45. Francki A. SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells J. Biol. Chem. 274 1999 32145 32152
46. Lane T.F. SPARC is a source of copper-binding peptides that stimulate angiogenesis J. Cell Biol. 125 1994 929 943
47. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis N. Engl. J. Med. 331 1994 1286 1292
48. Granucci F. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity EMBO J. 22 2003 2546 2551
49. Sivakumar P.V. Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses Immunology 112 2004 177 182
50. Aoki M. Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells Hypertension 38 2001 48 55
51. Heimberg H. Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis Diabetes 50 2001 2219 2224
52. Engleka K.A., Maciag T. Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation J. Biol. Chem. 267 1992 11307 11315
53. Hockel M. Purified monocyte-derived angiogenic substance (angiotropin) stimulates migration, phenotypic changes, and "tube formation" but not proliferation of capillary endothelial cells in vitro J. Cell. Physiol. 133 1987 1 13
54. Soncin F. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells Biochem. Biophys. Res. Commun. 236 1997 604 610
55. Folkman J., Shing Y. Angiogenesis J. Biol. Chem. 267 1992 10931 10934